NEWS

AmCham Norway, in partnerships with the US Chamber of Commerce and other AmChams in Europe, today shared concerns regarding the European intellectual property (IP) incentives review.

This exercise risks undermining the innovative industries at the cutting edge of medical innovation and discovery in the EU and more broadly.

Europe is at the forefront of healthcare innovation and IP protection, with 28 percent (60 million) of all European jobs tied directly to IP-intensive industries. According to the U.S. Chamber of Commerce’s Global Intellectual Property Index, European nations are among the global leaders in IP protection. Consequently, Europe is a top destination for investment, clinical trials, and diffusion of medical technologies.

Unfortunately, the Commission’s review of IP incentives risks sending the opposite signal as to the prospects of the European R&D sector and jeopardizing the EU’s industrial competitiveness and future growth.